ClinicalTrials.gg
Enrolling by invitationNCT07784751TPS-STROKEUpdated Aug 25, 2026

Safety, Dose-Finding, and Efficacy of Transcranial Pulse Stimulation for Post-Stroke Neurorehabilitation

A Phase 1/2 interventional study of Required Field in Ischemic Stroke, sponsored by Taipei Hospital, Ministry of Health and Welfare. Enrolling by invitation at 1 site in Taiwan. Per ClinicalTrials.gov, last updated 2026-08-25.

Sponsored by Taipei Hospital, Ministry of Health and Welfare · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies in Ischemic Stroke with a site in Taiwan — 18 open to participants now, 21 under way, 3 of them phase 3. Ischemic Stroke · Taiwan.

Planned enrollment
47th of 52
9 · median 73
Started
2026
with 4 others
Phase 1/2
3 of 64
1 open now
Primary completion
2027-08
later than 11 of 20 live
Registered
62nd of 64
by date

Among the 64 studies in Ischemic Stroke with a site in Taiwan, this one is the 47th largest by planned enrollment of the 52 interventional ones that give a count, is one of 5 that started in 2026, is one of 3 in phase 1/2, reaches primary completion later than 11 of the 20 other live ones, and was the 62nd registered.

Ischemic Stroke

2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

18 of the 64 studies in Ischemic Stroke with a site in Taiwan are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Ischemic Stroke with a site in Taiwan, or all of them as a file.
02

Study summary

This study aims to evaluate the safety, tolerability, dose-response, and preliminary efficacy of transcranial pulse stimulation (TPS) for neurorehabilitation in patients with ischemic stroke. Participants will receive TPS at different energy levels in a dose-escalation design. Clinical and neurophysiological assessments will be conducted to evaluate changes in motor function, balance, quality of life, and brain activity.

Read the detailed description

This is a prospective, interventional, non-randomized, open-label dose-finding study evaluating the safety, tolerability, and preliminary efficacy of transcranial pulse stimulation (TPS) in patients with ischemic stroke.

Participants will receive TPS using the NEUROLITH® TPS system (Storz Medical AG, Switzerland). The study will use a sequential dose-escalation design with three energy levels: 0.15, 0.20, and 0.25 mJ/mm². Each participant will receive TPS three times per week for 2 weeks, for a total of 6 treatment sessions. Each session will deliver 4,000 pulses at a frequency of 4 Hz.

The primary focus of the study is to evaluate the safety and tolerability of different TPS energy levels. Secondary and exploratory assessments will evaluate changes in motor function, balance, activities of daily living, quality of life, and neurophysiological measures. Electroencephalography (EEG) and functional near-infrared spectroscopy (fNIRS) will be used to assess changes in brain activity associated with treatment.

The study plans to enroll 9 participants initially, with 3 participants assigned to each dose level. Dose escalation will proceed after safety evaluation of the preceding dose level. If the predefined safety criteria are met, the study may be expanded to include additional participants.

03

Conditions studied

  • Ischemic Stroke

Browse trials for

Keywords

  • Transcranial Pulse Stimulation (TPS); Ischemic Stroke; Stroke Rehabilitation; Neurorehabilitation; Dose Escalation
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

  1. Age 20-80 years old.
  2. Confirmed ischemic stroke verified by MRI.
  3. Stroke onset between 1 month and 6 months prior to study enrollment.
  4. NIHSS score of 4-25 points, with quantifiable motor or language deficits.
  5. Completed acute medical care with stable vital signs.
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (estimated)

Study arms

  • Experimental
    0.15 → 0.20 → 0.25 mJ/mm²

    Participants will receive transcranial pulse stimulation (TPS) at an energy level of 0.15 mJ/mm², three times per week for 2 weeks, for a total of 6 treatment sessions. Participants will receive transcranial pulse stimulation (TPS) at an energy level of 0.20 mJ/mm², three times per week for 2 weeks, for a total of 6 treatment sessions. Participants will receive transcranial pulse stimulation (TPS) at an energy level of 0.25 mJ/mm², three times per week for 2 weeks, for a total of 6 treatment sessions.

    Device: Required Field

Interventions

  • DeviceRequired Field

    Participants will receive transcranial pulse stimulation (TPS) using the NEUROLITH® TPS system (Storz Medical AG, Switzerland). TPS will be administered at the assigned energy level of 0.15, 0.20, or 0.25 mJ/mm², at a frequency of 4 Hz, with 4,000 pulses per session. Treatment will be administered three times per week for 2 weeks, for a total of 6 treatment sessions. Dose escalation will proceed sequentially after safety evaluation of the preceding dose level.

06

What researchers measure

Primary outcomes

  1. Incidence of Dose-Limiting Toxicity (DLT) and Adverse Events

    Safety monitoring including adverse events (AEs), serious adverse events (SAEs), and DLT defined as: NIHSS increase ≥4 points lasting ≥24-48 hours, new-onset seizure, new or worsening neurological deficits, intolerable persistent AEs (headache, dizziness, nausea), or acute MRI worsening (new DWI stroke, hemorrhage, or severe edema).

    Time frame: Baseline, 2 weeks (immediately post-treatment), and 1 month post-treatment

07

Study locations

1 site
  • Huan-Jui
    Taipei, Taiwan 24213, Taiwan
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data will not be publicly shared to protect participant privacy and maintain confidentiality in accordance with institutional review board (IRB) guidelines and local data protection regulations.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Start Date: August 24, 2026. End Date: August 24, 2027 . For one year.

Access criteria: Inclusion Criteria Age 20-80 years. Confirmed ischemic stroke, supported by imaging (MRI). Stroke time between: subacute phase: more than 1 month to within 6 months of onset. NIHSS score 4-25, with objectively assessable motor or speech deficits. (Assessment at the time of consent signing) Acute phase medical treatment completed, vital signs stable.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Aug 2027, 12 months after the start.

Of 27 phase 1/2 interventional studies under Ischemic Stroke, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 76. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2026
First posted
Aug 25, 2026
StartActual
Aug 20, 2026
Primary completionEst.
Aug 24, 2027
CompletionEst.
Aug 24, 2027
Last update
Aug 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07784751
Lead sponsor
Taipei Hospital, Ministry of Health and Welfare
Collaborators
Chang Gung University, National Central University
Responsible party
YEH,YUAN-JUI (Chief, Department of Physical Medicine and Rehabilitation, Taipei Hospital, Ministry of Health and Welfare) — Principal investigator
First posted
Aug 25, 2026
Start date
Aug 20, 2026
Primary completion
Aug 24, 2027 (estimated)
Completion
Aug 24, 2027 (estimated)
Last update
Aug 25, 2026

Study contacts

Director, Department of Physical Medicine and Rehabilitation,
study director · Taipei Hospital, Ministry of Health and Welfare

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion